Clinical Trial Update: Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the peptide-based glioma vaccine IMA950 in patients with glioblastoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• IMA950

Snippet

Sponsor: Immatics Biotechnologies GmbH | Conditions: Glioblastoma | Phase 1 | Status: TERMINATED